Timothy W Lefever
Overview
Explore the profile of Timothy W Lefever including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jenkins B, Moore C, Covey D, McDonald J, Lefever T, Bonn-Miller M, et al.
Cannabis Cannabinoid Res
. 2023 Sep;
8(S1):S11-S24.
PMID: 37721993
Cannabis and its primary psychoactive constituent delta-9-tetrahydrocannabinol (D9-THC) produce biphasic, dose-dependent effects on anxiety. In addition to D9-THC, cannabis contains other "minor" cannabinoids and terpenes with purported therapeutic potential for...
2.
Moore C, Marusich J, Haghdoost M, Lefever T, Bonn-Miller M, Weerts E
Cannabis Cannabinoid Res
. 2023 Sep;
8(S1):S42-S50.
PMID: 37721992
Cannabis contains a multitude of phytocannabinoids and terpenes in addition to its main psychoactive constituent, delta-9-tetrahydrocannabinol (D9-THC). It is believed that the combination of minor cannabinoids and terpenes with D9-THC...
3.
Kulpa J, Henderson R, Schwotzer D, Dye W, Trexler K, McDonald J, et al.
Cannabis Cannabinoid Res
. 2023 Sep;
8(S1):S25-S41.
PMID: 37721989
Despite growing consumer interest and market availability, the safety of minor cannabinoids, generally present in low concentrations in L., is not well understood. Cannabichromene (CBC; 3.2, 10, 17, 22, 32,...
4.
Moore C, Weerts E, Kulpa J, Schwotzer D, Dye W, Jantzi J, et al.
Cannabis Cannabinoid Res
. 2023 Sep;
8(S1):S51-S61.
PMID: 37721988
Minor cannabinoids are increasingly being consumed in oral formulations (i.e., edibles, tinctures) for medical and nonmedical purposes. This study examined the pharmacokinetics (PKs) of cannabinoids tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabinol...
5.
Henderson R, Welsh B, Trexler K, Bonn-Miller M, Lefever T
Regul Toxicol Pharmacol
. 2023 Jun;
142:105425.
PMID: 37271419
Consumer use of cannabidiol (CBD) for personal wellness purposes has garnered much public interest. However, safety-related data on CBD in the public domain are limited, including a lack of quality...
6.
Henderson R, Lefever T, Heintz M, Trexler K, Borghoff S, Bonn-Miller M
Food Chem Toxicol
. 2023 Apr;
176:113778.
PMID: 37105391
Use of cannabidiol (CBD) in humans has increased considerably in recent years. While currently available studies suggest that CBD is relatively safe for human consumption, data from publicly available studies...
7.
Henderson R, Welsh B, Rogers J, Borghoff S, Trexler K, Bonn-Miller M, et al.
Food Chem Toxicol
. 2023 Apr;
176:113786.
PMID: 37105390
An important data gap in determining a safe level of cannabidiol (CBD) intake for consumer use is determination of CBD's potential to cause reproductive or developmental toxicity. We conducted an...
8.
Land M, Toth M, MacNair L, Vanapalli S, Lefever T, Peters E, et al.
Cannabis Cannabinoid Res
. 2021 May;
6(6):522-527.
PMID: 33998871
Despite widespread use of cannabidiol (CBD), no lifelong toxicity study has been published to date. is often used in preclinical lifelong toxicity studies, due to an estimated 60-80% of their...
9.
Wiley J, Barrus D, Farquhar C, Lefever T, Gamage T
Prog Neuropsychopharmacol Biol Psychiatry
. 2020 Aug;
106:110064.
PMID: 32810571
Cannabis edibles are becoming more common in an increasingly diverse population of users, and the impact of first pass metabolism on cannabis's pharmacological profile across age and sex is not...
10.
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018
Gamage T, Barrus D, Kevin R, Finlay D, Lefever T, Patel P, et al.
Pharmacol Biochem Behav
. 2020 Apr;
193:172918.
PMID: 32247816
Synthetic cannabinoid receptor agonists (SCRAs) possess high abuse liability and complex toxicological profiles, making them serious threats to public health. EG-018 is a SCRA that has been detected in both...